Skip to main content
Clinical Trials/NL-OMON44525
NL-OMON44525
Completed
Not Applicable

Study of the Safety and Efficacy of Neurostimulation of the Cholinergic Anti-Inflammatory Pathway Using a Vagal Nerve Stimulation Device in Patients with Active Refractory Crohn*s Disease - SPM-007

SetPoint Medical Corporation0 sites3 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Crohn's Disease
Sponsor
SetPoint Medical Corporation
Enrollment
3
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • \-Male or female subjects aged 18\-75 years, inclusive
  • \-Written informed consent prior to any of the screening procedures
  • \-Diagnosis of Crohn's disease for more than 4 months prior to Week \-4 Visit, with small bowel and/or colonic involvement
  • \-Current evidence of moderately\-to\-severely active disease defined by a Week \-4 Visit Crohn's Disease Activity Index (CDAI) score of 220 to 450,
  • \-Simple Endoscopic Score for Crohn\*s Disease evaluation at baseline showing presence of a minimal ulcer score of 2 or 3 in at least 1 segment
  • \-Levels of fecal calprotectin greater than or equal to 200 microgram/gram feces at Week \-4 Visit
  • \-History of inadequate response and/or intolerance or adverse events to one or more TNF\-alpha inhibitors (e.g., infliximab, adalimumab, or certolizumab pegol) or vedolizumab.
  • \-Female subjects of child\-bearing potential are eligible if not pregnant, not planning to become pregnant during the course of the study, and committed to use of contraceptive methods with a failure rate of less than 1 percent per year

Exclusion Criteria

  • Patients who meet any of the following criteria are not to be enrolled in this study:
  • \-Celiac disease
  • \-Diagnosis of ulcerative or indeterminate colitis
  • \-Enterocutaneous, abdominal or pelvic fistulae with abscesses, or fistulae likely to require surgery during the course of the study period
  • \-Bowel surgery, other than appendectomy, within 12 weeks prior to Week \-4 Visit and/or has planned surgery or deemed likely to need surgery for Crohn's disease during the study period
  • \-Extensive colonic resection, subtotal or total colectomy
  • \-Presence of ileostomies, colostomies or rectal pouches
  • \-Fixed symptomatic stenoses of small bowel or colon
  • \-History of more than 3 small bowel resections or diagnosis of short bowel syndrome
  • \-Use of prohibited medications inside the specified washout period (prior to Week \-4 Visit), and throughout the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials